Live Earnings Conference Call: Elite Pharmaceuticals had a scheduled live Q1 2027 earnings call on August 14, 2026 at 11:30AM ET. OTCMKTS:ELTP Elite Pharmaceuticals Q1 2027 Earnings Report $0.32 -0.04 (-12.13%) As of 02:17 PM Eastern ProfileEarnings History Live Call not available Upcoming EventEarnings Conference CallElite Pharmaceuticals Q1 202700:00 / 00:00Live Transcript Follow Audio Elite Pharmaceuticals EPS ResultsActual EPS$0.01Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AElite Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AElite Pharmaceuticals Announcement DetailsQuarterQ1 2027Date8/13/2026TimeAfter Market ClosesConference Call DateFriday, August 14, 2026Conference Call Time11:30AM ETUpcoming EarningsElite Pharmaceuticals' Q2 2027 earnings is estimated for Friday, August 14, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Elite Pharmaceuticals Earnings HeadlinesElite Pharmaceuticals, Inc.: Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call ...August 13 at 7:04 PM | finanznachrichten.deElite Pharmaceuticals to Announce Q1 2027 ResultsAugust 12 at 8:59 AM | theglobeandmail.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.August 14 at 1:00 AM | Stansberry Research (Ad)Elite Pharmaceuticals (OTCMKTS:ELTP) Stock Crosses Below 200 Day Moving Average - Here's What HappenedAugust 12 at 3:21 AM | americanbankingnews.comElite Pharmaceuticals (OTCMKTS:ELTP) Stock Price Passes Below Two Hundred Day Moving Average - Time to Sell?August 4, 2026 | americanbankingnews.comElite Pharmaceuticals Inc (ELTP) Q4 2026 Earnings Call Highlights: Record Revenue Growth and ...July 1, 2026 | finance.yahoo.comSee More Elite Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Elite Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Elite Pharmaceuticals and other key companies, straight to your email. Email Address About Elite PharmaceuticalsElite Pharmaceuticals (OTCMKTS:ELTP), Inc. is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care. Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities. The company collaborates with contract manufacturing organizations and leverages distribution networks to supply products to wholesalers, hospitals and healthcare providers across the United States. Through these alliances, Elite Pharmaceuticals aims to streamline supply chains and enhance product availability for its key markets. Specific information on the company’s leadership team and key historical milestones is limited in publicly available sources. Industry records indicate the management group brings experience in pharmaceutical sourcing, regulatory affairs and product development. Elite Pharmaceuticals continues to explore opportunities for organic growth, business development and potential acquisitions, positioning itself to capitalize on innovation within the specialty pharmaceutical sector.View Elite Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Cerebras Sells Off After Earnings: Is This a Market Disconnection?Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?Sandisk’s Margins Look Like Software. Can They Last?SpaceX’s First Earnings Report Only Made Wall Street More DividedCAVA Earnings: The Easiest Comp of the Year Meets a Tough ValuationQuantum Leaps: Debt-Free as AI Storage Demand AcceleratesFranco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care? Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
